#United States #New York #Alzheimer's Drug Discovery Foundation #Gavin Cook #David Dolby

Strengthening Leadership at ADDF

The Alzheimer's Drug Discovery Foundation (ADDF) is embarking on a significant transition as it enhances its leadership to address the urgent challenges in Alzheimer's research. With the appointment of two new members to its Board of Governors, Gavin Cook and David Dolby, alongside Jane McIntosh stepping in as the Interim Chief Executive Officer, ADDF is strategically positioning itself for advancements in the field.

New Board Members Bringing Expertise

Gavin Cook is currently the Executive Director of Global Alzheimer's Disease Commercial at Eisai US, where he has played a pivotal role in bringing innovative treatments to the market. His extensive experience in pharmaceutical development will be invaluable to ADDF as it seeks to drive forward drug discovery and clinical research focused on Alzheimer's.

David Dolby, a thriving force in venture capital as the CEO of Dolby Family Ventures, brings significant investment expertise that will augment ADDF's efforts to foster partnerships and secure funding. His previous roles include directorships at Dolby Laboratories and Cogstate Limited, equipping him with rich insights into both technological and operational aspects of biomedical innovation.

By incorporating these leaders into the governance structure, the ADDF is set to amplify its strategic vision and operational capacity amid an evolving landscape in Alzheimer's research, particularly as rapid scientific advancements emerge.

A New Chapter with Interim Leadership

In tandem with the Board's expansion, Jane McIntosh's appointment as Interim CEO marks a crucial moment for the organization. With a career spanning over two decades in nonprofit leadership, McIntosh has accrued a wealth of experience in philanthropy and public engagement, serving as the ADDF's Chief Philanthropy and External Affairs Officer since 2021. She is stepping up during a transformative phase for the ADDF, following Mark Roithmayr, the organization’s inaugural CEO, who held the position for nine years.

In her new capacity, McIntosh aims to assure stakeholders of ADDF’s continued leadership in advancing Alzheimer's science. "This is an exciting moment for the Alzheimer's field, with potential for breakthroughs in precision medicine that could redefine treatment pathways,” McIntosh stated, expressing her commitment to leading the organization towards achieving meaningful progress in patient care.

Promising Future for Alzheimer's Research

As the Alzheimer’s landscape shifts with promising scientific breakthroughs, the role of the ADDF is more critical than ever. The foundation's mission—to prevent, treat, and cure Alzheimer's disease—remains at the forefront of its strategic endeavors. Leveraging the expertise of its new board members alongside a dedicated interim CEO, ADDF is poised to accelerate an agenda vital for addressing this pressing public health challenge.

The collective efforts of this newly augmented leadership promise to enhance collaboration, drive innovation, and ensure that the foundation remains a pivotal player in the quest for effective treatments for Alzheimer’s.

Conclusion

Driven by its new leadership structure, the ADDF is aligned with the needs of researchers, patients, and families affected by Alzheimer’s as it navigates this crucial time. As it looks ahead, the foundation is ideally positioned to champion the next generation of Alzheimer's research and therapeutic development, reinforcing its commitment to changing lives through science and collaboration.

For those interested in following ADDF's journey or contributing to its mission, further information is available at ADDF's official website.